Shares kick on open as BOD Australia releases double dose of good news

By Trevor Hoey. Published at May 18, 2021, in ASX Biotechs

Medicinal Cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX:BDA) has provided a promising update on its new medicinal cannabis product launch, as well as highlighting recent MediCabilisTM prescription growth in the United Kingdom.

Such was the positive response to today’s news that the company’s shares traded approximately 9% higher shortly after the market opened.

BDA is launching a new cannabigerol (CBG) product, which will be sold under the MediCabilis brand as MediCabilisTM CBG 50 in the United Kingdom.

CBG is a non-intoxicating cannabinoid compound in the cannabis plant, which holds strong therapeutic potential for use in broad therapeutic applications.

Preliminary research indicates that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD.

CBG has a different chemical structure to CBD and THC and will bind onto specific cell receptors for different therapeutic targets.

BDA is launching the product following R&D assessments, with the introduction being part of the management’s approach to developing specific cannabis cultivators and product formats for current and future new product development.

The market for CBG is in its early stages and is expected to grow significantly in the coming years.

First mover advantage with CBG 50 offers competitive benefits

The launch of MediCabilisTM CBG 50 will provide BDA with a first-mover position that will provide competitive advantages going forward.

Initially, BDA will focus on launching the product in the UK through select doctors and healthcare physicians.

The introduction of MediCabilisTM CBG 50 is also expected to support incremental market growth across the region, as well as providing additional R&D and clinical research opportunities.

Discussing these developments, chief executive Jo Patterson said, “The launch of a new CBG product, under the widely recognised MediCabilisTM brand will provide the company with a number of opportunities to increase prescription sales and scale up R&D.

"CBG has been reported to be the ‘next CBD’ and has a growing market demand.

"Published scientific literature suggests that CBG has potential anti-inflammatory benefits, so the launch of MediCabilisTM CBG 50 in oil form will provide Bod with an important first-mover advantage in what will become a significant market.’’

Quarter-on-quarter MediCabilisTM prescription growth an impressive 90%

In another positive development, BDA has reported strong quarter-on-quarter MediCabilisTM prescription growth in the UK.

During the March quarter of fiscal 2021, the company filled a total of 59 MediCabilisTM units, marking a 90% increase on the previous quarter (Q2 FY2021 prescriptions: 31).

BDA expects that UK MediCabilisTM prescription volumes will continue an upward trajectory following the launch of the company’s new CBG product, Project Twenty21 scale-up and ongoing educational initiatives to promote the company’s products with approved prescribers in the UK market.

Discussing the group’s strategy in relation to growing market share, Patterson said, "The recent upward trajectory in MediCabilisTM prescriptions is also very pleasing and follows considerable hard work undertaken in collaboration with our distribution partners and approved prescribers in the UK.

"To further scale up UK medicinal cannabis sales, Bod is progressing educational initiatives, as well as working with large industry bodies to grow its market share.

"This is a similar approach to how the company has tackled the Australian market and we expect growth to continue over the remainder of the calendar year and beyond.”


View Our Investment Portfolios


S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X